Literature DB >> 7986888

Noradrenergic and adrenergic functioning in autism.

R B Minderaa1, G M Anderson, F R Volkmar, G W Akkerhuis, D J Cohen.   

Abstract

A neurochemical assessment of noradrenergic and adrenergic functioning was carried out with autistic patients and normal control individuals. Norepinephrine and related compounds were measured in autistic (n = 17 unmedicated, 23 medicated; age range 9-29 years old) and normal controls (n = 27; age range 9-36 years old). Plasma levels and urinary excretion of 3-methoxy-4-hydroxy-phenylglycol (MHPG) were measured, as were urinary excretion rates of norepinephrine (NE), epinephrine (EPI), and vanillylmandelic acid (VMA). No significant group mean differences were seen between the autistic and control groups. In both the autistic and control groups urinary excretion rates of norepinephrine and epinephrine were substantially higher in the afternoon-evening (5-11 PM) compared to the overnight (11 PM-7 AM) collection period. Based on our neurochemical assessment, marked abnormalities in basal noradrenergic functioning do not appear to be present in autism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986888     DOI: 10.1016/0006-3223(94)90605-x

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

1.  Pupil and salivary indicators of autonomic dysfunction in autism spectrum disorder.

Authors:  Christa J Anderson; John Colombo; Kathryn E Unruh
Journal:  Dev Psychobiol       Date:  2012-05-29       Impact factor: 3.038

Review 2.  Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.

Authors:  Logan K Wink; Martin H Plawecki; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

3.  Autonomic and neuroendocrine responses to a psychosocial stressor in adults with autistic spectrum disorder.

Authors:  Lucres M C Jansen; Christine C Gispen-de Wied; Victor M Wiegant; Herman G M Westenberg; Bertine E Lahuis; Herman van Engeland
Journal:  J Autism Dev Disord       Date:  2006-10

Review 4.  A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder.

Authors:  Sushmitha S Purushotham; Neeharika M N Reddy; Michelle Ninochka D'Souza; Nilpawan Roy Choudhury; Anusa Ganguly; Niharika Gopalakrishna; Ravi Muddashetty; James P Clement
Journal:  Exp Brain Res       Date:  2022-09-05       Impact factor: 2.064

Review 5.  The serotonin system in autism spectrum disorder: From biomarker to animal models.

Authors:  C L Muller; A M J Anacker; J Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

6.  Effect of propranolol on functional connectivity in autism spectrum disorder--a pilot study.

Authors:  Ananth Narayanan; Catherine A White; Sanjida Saklayen; Mary J Scaduto; Allen L Carpenter; Amir Abduljalil; Petra Schmalbrock; David Q Beversdorf
Journal:  Brain Imaging Behav       Date:  2010-06       Impact factor: 3.978

7.  Sleep behaviors and sleep quality in children with autism spectrum disorders.

Authors:  Margaret C Souders; Thorton B A Mason; Otto Valladares; Maja Bucan; Susan E Levy; David S Mandell; Terri E Weaver; Jennifer Pinto-Martin
Journal:  Sleep       Date:  2009-12       Impact factor: 5.849

8.  Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study.

Authors:  Rachel M Zamzow; Bradley J Ferguson; Janine P Stichter; Eric C Porges; Alexandra S Ragsdale; Morgan L Lewis; David Q Beversdorf
Journal:  Psychopharmacology (Berl)       Date:  2016-01-14       Impact factor: 4.530

Review 9.  The Role of the Noradrenergic System in Autism Spectrum Disorders, Implications for Treatment.

Authors:  David Q Beversdorf
Journal:  Semin Pediatr Neurol       Date:  2020-06-24       Impact factor: 1.636

10.  Monoamine oxidase A and A/B knockout mice display autistic-like features.

Authors:  Marco Bortolato; Sean C Godar; Loai Alzghoul; Junlin Zhang; Ryan D Darling; Kimberly L Simpson; Valentina Bini; Kevin Chen; Cara L Wellman; Rick C S Lin; Jean C Shih
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-31       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.